Skip to main content
. Author manuscript; available in PMC: 2014 Feb 1.
Published in final edited form as: Neuropharmacology. 2012 Oct 16;65:156–164. doi: 10.1016/j.neuropharm.2012.08.022

Figure 4. The α7 nAChR type I PAM NS1738 did not attenuate chronic constriction injury (CCI)-induced thermal hyperalgesia in mice.

Figure 4

Ten days after chronic constriction injury, mice were pretreated with either vehicle or NS1738, and then tested 15, 60, 180 and 360 min later in the Hargreaves plantar stimulator test. NS1738 (30mg/kg, i.p.) did not attenuate CCI-induced thermal hyperalgesia. Sham group did not differ between vehicle and drug treatment groups (data not shown). Results were expressed as means ± SEM paw latencies in s from ipsilateral and contralateral paws (n = 6–8 mice per group). *p < 0.05 when compared to contralateral paw latency. Veh = vehicle; NS = NS1738.